In the BioHarmony Drug Report Database

"Preview" Icon

Telmisartan

Micardis, Kinzalmono, Pritor, Telmisartan Boehringer Ingelheim Pharma KG (telmisartan) is a small molecule pharmaceutical. Telmisartan was first approved as Micardis on 1998-11-10. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat hypertension. The pharmaceutical is active against type-1 angiotensin II receptor. In addition, it is known to target peroxisome proliferator-activated receptor gamma. Micardis’s patent is valid until 2022-10-06 (FDA).

 

Trade Name

 

Kinzalmono, Micardis, Pritor, Telmisartan Boehringer Ingelheim Pharma KG
 

Common Name

 

telmisartan
 

ChEMBL ID

 

CHEMBL1017
 

Indication

 

diabetic nephropathies, heart failure, hypertension, left ventricular dysfunction
 

Drug Class

 

Angiotensin II receptor antagonists

Image (chem structure or protein)

Telmisartan structure rendering